European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects

Published:2019-02-05 Issue:1 Volume:475 Page:25-37
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Keppens Cleo,Dufraing Kelly,van Krieken Han J.,Siebers Albert G.,Kafatos George,Lowe Kimberly,Demonty Gaston,Dequeker Elisabeth M. C.

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s00428-019-02525-9/fulltext.html

Reference29 articles.

1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66(4):683–691. https://doi.org/10.1136/gutjnl-2015-310912

2. Dattatreya S (2013) Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2(3):179–185. https://doi.org/10.4103/2278-330X.114152

3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634. https://doi.org/10.1200/JCO.2007.14.7116

4. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023–1034. https://doi.org/10.1056/NEJMoa1305275

5. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomised, multicentre phase II study of panitumumab plus modified fluouracil, leucovorin, and oxiplatin (mFOLFOX6) or bevacizumab plus FOLFOLX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorecatal cancer. J Clin Oncol 53:2473–2247. https://doi.org/10.1200/JCO.2013.53.2473

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal analysis of 20 Years of external quality assurance schemes for PCR/NAAT-based bacterial genome detection in diagnostic testing;Frontiers in Molecular Biosciences;2024-03-27

2. The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories;Cancers;2022-07-28

3. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems;Seminars in Cancer Biology;2021-08

4. Frequency of Participation in External Quality Assessment Programs Focused on Rare Diseases: Belgian Guidelines for Human Genetics Centers;JMIR Medical Informatics;2021-07-12

5. Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database;Future Oncology;2021-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3